Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide oral formulations pharmacokinetics in healthy males
NCT06642584Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoints: Area Under the Semaglutide Plasma Concentration-Time Curve, Maximum Observed Semaglutide Plasma Concentration and 2 more. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06642584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642584.